British Business Bank

The Bank's 2026 Small Business Equity Tracker, published on 2 July, put a number on the market it has spent the year trying to rebalance: AI companies took a record 44% share of UK smaller-business equity value in 2025 even as the overall market shrank 4% to £12.3bn, with the top 10 fundraisings alone absorbing 23% of all investment and seed deals falling 27%. London's own share of that shrinking pot slipped from 60% to 57%, as the North West, Scotland and the South West posted outsized gains built on a handful of large AI and energy deals rather than broader regional strengthening. University spinout deals, the tier the Bank's Longwall Ventures cornerstone targets, fell 33% by count and 51% by value, with 36.7% of 2025 spinout rounds closing below £500,000.

The British Business Bank received an additional £6.6bn mandate from April 2026, authorising it for the first time to lead venture rounds and invest directly in startups at up to £60m per company. A new £4bn Industrial Strategy Growth Capital Initiative targets eight priority sectors. In the six weeks following mandate activation, the Bank deployed capital across five direct deals: £40m cornerstone into Quantum Motion's £160m Series c (the Bank's largest single direct cheque); £13m into Elliptic's $120m Series D via both its British Growth Partnership Fund I and the core balance sheet; £12m into Cytospire Therapeutics' oversubscribed Series A; an anchor LP position in Lansdowne Partners' €128.9m first close; and on 27 May 2026, a £50m cornerstone commitment to Longwall Ventures Fund 4 via the Enterprise Capital Funds programme. Longwall 4 targets £100m and had reached £86.2m; it writes £500,000 to £2m cheques into 14 to 16 early-stage deeptech firms across advanced manufacturing, clean energy, defence and life sciences — the precise band Left structurally underfunded by the April 2026 VCT relief cut from 30% to 20%. Longwall's Fund 1 backed OrganOx, sold to Japan's Terumo in 2025 for more than $1.5bn, a 19.2x return for the Bank.

The British Business Bank was established in 2014 as a government-owned development bank to address gaps in business finance. Over its first decade it became the UK's largest domestic investor in venture capital funds, supporting more than 200,000 businesses and deploying £6.3bn of public funding alongside £10bn in lending guarantees. Its historic role was as a limited partner in VC funds rather than a direct investor; the April 2026 reforms changed this model. The Bank also marked the two-year milestone of the Northern Powerhouse Investment Fund II with £275m deployed across 449 deals, of which £151.3m was direct BBB capital alongside £122.6m from private co-investors — a 44% private leverage ratio.

The Bank's deployment pattern now spans both ends of the capital stack simultaneously: cornerstone cheques into seed-tier deeptech funds (Longwall) and direct growth-equity investments at Series c and beyond (Quantum Motion). This barbell position is a deliberate response to the bifurcated UK venture market, where a record $10.5bn in January to April 2026 funding (GlobalData) masks a 2% fall in deal volume and over 40% of capital concentrated in three mega-rounds. It operates alongside the Sovereign AI Unit as part of a coordinated public capital stack designed to prevent high-growth UK scale-ups relocating abroad for growth capital. The Bank's small-ticket participation in Exeter spinout Neuronostics' £3m BioEP round on 30 June, alongside The FSE Group and a blended Innovate UK grant, is the same seed-tier logic in miniature: a modest cheque alongside specialist co-leads rather than a cornerstone position.